The Sardinian population is genetically homogeneous and could be useful in understanding better the genetics of a complex disease like breast cancer (BC).
Introduction
Germline mutations in BRCA1 (MIM 113705) and BRCA2 (MIM 600185) account for cancer predisposition in the majority of families with recurrence of breast malignancies.
Previous studies using linkage analysis have suggested that germline mutations in BRCA1 and BRCA2 account for >90% of rigorously defined families with both breast cancer (BC) and ovarian cancer [1] [2] [3] . In a more comprehensive analysis presented by the Breast Cancer Linkage Consortium on about 200 families with at least four cases of BC and any number of ovarian cancers, 81% of the breast-ovarian cancer families presented with BRCA1 mutations whereas 14% of them were associated with BRCA2 [4] . Moreover, 76% of the families with male and female BC were associated with BRCA2 mutations [4] [5] [6] . Generally, the probability of finding a mutation within these two susceptibility genes in a BC patient increases with the number of related cases of early-onset BC or ovarian cancer in the family [7] .
For BC, risk ratios have been demonstrated to increase with increasing numbers of affected first-degree relatives [7] . The cumulative lifetime risk, to age 70 years, of developing female BC in BRCA1/2 mutation carriers from multiple-case families has been estimated to be approximately 80% [4, [7] [8] [9] . Germline BRCA1/2 mutations have been also associated, in both sexes, with elevated risks for cancers at multiple organ sites, including prostate and gastrointestinal tumors [10, 11] .
To date, several distinct mutations have been identified throughout the entire coding sequence of both BRCA1 and BRCA2 genes. Highly recurrent founder mutations have been described in genetically homogeneous populations or ethnic groups. While a single BRCA2 mutation accounts for the majority of hereditary BCs in Iceland [12] , three different BRCA1/2 mutations have been described at high frequency among Ashkenazi Jews [13] and an even higher number (12) of recurrent founder mutations account for the vast majority of Finnish BRCA1/2 families [14] [15] [16] .
High frequencies of BRCA1 and/or BRCA2 mutations were also observed in BC patients unselected for family history from these genetically homogeneous populations, with the highest frequencies observed among the Ashkenazi Jews (20-30%, depending on the age of onset) [17, 18] . Conversely, studies performed on unselected BC patients from different populations revealed that frequencies of BRCA1/2 mutations were considerably lower [19] [20] [21] .
In Sardinia, whose population is also genetically homogeneous (living for several hundred years in a roughly homogeneous environment), BC represents the principal death-causing malignancy as assessed by the Regional Tumor Registry [22] , with an incidence of 93 per 100 000 inhabitants (standardized rate). In a previous study, we have identified a BRCA2 'frameshift' mutation at codon 2867 (8765delAG), causing a premature termination codon and showing a founder effect among seven unrelated BC families from North Sardinia [23] . To evaluate extensively the prevalence and spectrum of BRCA1 and BRCA2 mutations in the BC population from this region, BC families with at least three affected members were analyzed for mutations throughout the entire coding sequence of both BRCA1 and BRCA2 genes. The proportion of families in which BC is due to BRCA1/2 germline mutations has been estimated, and the cancer phenotype of families either positive or negative for such mutations has been defined.
Patients and methods

Family selection
Forty-seven families with at least three cases of BC from two different generations and at least one of them diagnosed before the age of 50 or at least one case of male BC diagnosed at any age were included in this study. In Table 1 , families are categorized according to the number of BC cases, the presence of ovarian cancer or male BC, and the distribution of cases through generations. Families were ascertained through specific cancer evaluation programs at the University of Sassari (which represents the principal institution accounting for the majority of cancer patients from the northern-central part of the island). Briefly, women with histologically documented diagnosis of BC and regularly followed at the different departments of the participating institutions were invited to participate in interviews on their family history of cancer. All information regarding the recurrence of cancers in the family, age at cancer diagnosis and age at death or current age was collected after obtaining written informed consent. Most of the information was verified by analysis of the hospital records; all cancer diagnoses were confirmed by pathology reports for all probands as well as for all affected relatives. After the patients were informed about the aims and limits of BC genetic testing, blood samples were obtained with their written consent (in any case, documentation of counseling was carefully evaluated prior to genetic testing). DNA samples were collected from at least one affected member of each family. The study was reviewed and approved by the ethical review boards of both Institutions (University and Azienda Sanitaria Locale of Sassari).
DNA analysis
Genomic DNA for mutational analysis of the 47 BC families was isolated from peripheral blood samples of 59 affected members, using standard methods. In Table 1 , all familial cases tested for BRCA1 and BRCA2 mutations are listed according to the age at diagnosis. Mutational analysis of the complete coding sequence and intron-exon boundaries of the BRCA1 and BRCA2 genes was performed by a combination of techniques: single-strand conformation polymorphism (SSCP), denaturing high-performance liquid chromatography (DHPLC), and direct sequencing.
The 22 coding exons and flanking splice site regions of BRCA1 were amplified under standard polymerase chain reaction (PCR) conditions, using 32 sets of primers (11 sets of overlapping primers were used for amplification of exon 11). Similarly, the 26 coding exons of BRCA2 and their flanking intron-exon junctions were amplified using 56 sets of primers (with overlapping primer sets for exons 10, 11, 14, 18 and 27) . All primer sequences are available on request. All PCR products were run in SSCP electrophoresis gels under different conditions as previously described [23] . Suspected variants were identified as having a mobility shift. For a large fraction of cases (32 probands; particularly from families with higher recurrence of BC) mutational screening was also performed by DHPLC (demonstrated to be more sensitive than SSCP analysis in detecting genetic variants [24] ), using the WAVE Nucleic Acid Fragment Analysis System (Transgenomic, Omaha, NE, USA). Suspected variants are visualized as a characteristic pattern of peaks corresponding to the mixture of homo-and heteroduplexes formed when wild-type and mutant DNA are hybridized. All abnormal PCR products identified by both methods were directly sequenced using an automated fluorescence-based cycle sequencer (ABIPRISM 3100; Perkin Elmer, Foster City, CA, USA).
To confirm that each germline BRCA1/2 variant detected by sequencing was a real mutation and not a polymorphism, 53 unrelated normal individuals (corresponding to 106 chromosomes), originating from the same geographical area and with no family history of BC, were used as controls and screened for each gene variant identified.
Genomic DNA for mutational screening of 501 unselected BC patients was isolated from both peripheral blood samples (n = 51) and archival paraffin-embedded tissues (n = 450), using previously described procedures [23] . To avoid any bias, paraffin-embedded normal tissues from BC patients were consecutively collected at the University of Sassari during two entire years (1997 and 1998). All cases were thus included regardless of age at diagnosis, family history status and disease features. Sardinian origin was ascertained in all cases through genealogical studies.
Results
Family screening
DNA from 59 BC patients as probands of the 47 selected families was screened for germline mutations of BRCA1 and BRCA2 genes. Mutational detection for all coding regions and splice boundaries of these two genes was performed by SSCP and DHPLC analysis (see Patients and methods); all PCR products presenting an abnormal mobility or denaturing profile in comparison with the normal controls were sequenced using an automated approach.
As shown in Table 2 , only three germline variants were detected, at exon 11 of BRCA1 and exons 20 and 27 of BRCA2. Although BRCA2-8765delAG, which we previously described as a frameshift mutation with a founder effect in North Sardinia [23] , remained the only recurrent mutation among families from the same geographical area, its prevalence was demonstrated to be much lower than that which we reported for the first seven families [six of 47 (12.8%) versus four of seven (57%), respectively] ( Table 2 ). The remaining two sequence variations, BRCA1-Lys505ter and BRCA2-Ile3412Val, were identified in two additional different families. BRCA2-Ile3412Val has been previously reported as a rare missense variant (Table 2) , with uncertain significance on function [25] (a prevalence study of simple sequence variations in the BRCA2 gene using 332 chromosomes from worldwide populations strongly suggests that Ile3412Val cannot be considered as a disease-causing mutation [26] ). BRCA1-Lys505ter is a nonsense mutation ( Table 2 ) that was absent in blood DNA from 53 unrelated normal individuals (corresponding to 106 control chromosomes) and has not been reported before in databases. Interestingly, BRCA1-Lys505ter was detected in the family presenting the strongest association between breast and ovarian cancer in our cohort ( Figure 1 ). Because of both their predicted effects on proteins and their absence in normal controls, BRCA2-8765delAG and BRCA1-Lys505ter were the disease-causing mutations identified in seven of 47 (15%) families. Figure 2 shows the nucleotide sequences corresponding to these mutations.
As shown in Table 3 , ovarian cancer was found associated only in three (6%) BC families, with two of them positive for BRCA1/2 mutations. Although no statistical analysis was undertaken to investigate the association with other tumors, the number of familial members with prostate cancer and bladder cancer was higher in BRCA1/2-positive than BRCA1/2-negative families [six of 15 (40%) versus five of 39 (13%) for prostate cancer, and three of 15 (20%) versus two of 39 (5%) for bladder cancer, respectively] ( Table 3) . Considering all families due to BRCA1/2, the proportion of mutations was strikingly different when we analyzed different subgroups. As shown in Table 4 , the increasing number of female BC cases was significantly correlated with the presence of a BRCA1/2 mutation in the families (significance of linearity, P <0.01; Pearson's Chi-square test). In addition, the presence of ovarian cancer, male BC, or three affected generations were all factors raising the incidence of BRCA1/2 mutations in the families (Table 4) . 
Unselected BC patient screening
To evaluate the prevalence of BRCA2-8765delAG in the BC population from Sardinia, we screened 501 genomic DNA samples (from both peripheral blood and, mainly, paraffinembedded normal tissues) from consecutively collected BC patients. As previously described [23] , the 2-bp deletion mutation was detected as a size variant using conventional electrophoresis (the two alleles were easily visualized by silver staining). The BRCA2-8765delAG mutation was found in seven cases (1.4%). Pedigree analysis of these patients revealed that two of them originated from the same small village (Thiesi) and had a common ancestor in 1700, thus belonging to the same family ( Figure 3 ). In addition, screening for the BRCA1-Lys505ter mutation on the available 93 blood DNAs from unselected BC patients revealed the presence of one case (1%) carrying this sequence variation (in Figure 1 , the pedigree of this positive case is shown). Interestingly, all BC patients found positive for BRCA2-8765delAG or BRCA1-Lys505ter were from seven families presenting the same features included in the previously described selection criteria (see Patients and methods). In Table 3 , the seven families identified by screening of unselected cases are indicated by asterisks.
Finally, BC patients with synchronous or asynchronous bilateral tumors presented a 10-fold higher incidence of the BRCA2-8765delAG mutation in comparison with those with unilateral BC [four of 13 (30.8%) versus 17 of 547 (3.1%), respectively].
Discussion
The present study represents the first in which an extensive mutation analysis in the coding regions and splice boundaries of the BRCA1 and BRCA2 genes has been performed in Sardinian BC families. Sardinia has a relatively small and isolated population with a relatively high rate of inbreeding, all factors that increase genetic homogeneity and should be helpful in defining the genetic counterpart of multifactorial diseases (including cancer) [27] . After a molecular screening based on a combination of SSCP and DHPLC, and sequence analysis, two deleterious BRCA1/2 mutations were found in seven (15%) out of 47 BC families. In addition, we evaluated the frequency of the most recurrent mutation identified in this study, BRCA2-8765delAG [observed in six of eight (75%) BRCA1/2-positive families], which was detected in seven of Table 3 ). 501 (1.4%) unselected and consecutively collected BC patients from the same geographical area.
Also taking into consideration some lack of sensitivity of our screening assay to reduce the number of positive cases, the prevalence of BRCA1/2 mutations in Sardinian families with at least three affected members remains low (although quite similar to that reported in the Finnish population [14] ). When we restricted the analysis to BC families selected towards higher risk (four cases or more affected by breast or ovarian cancer), the proportion of families due to BRCA1/2 mutations Tables 3 and 4 ]. However, this prevalence was still lower than that reported in Ashkenazi Jews or in other genetically homogeneous populations (such as Icelandic and French-Canadian), where few founder mutations in BRCA1 and BRCA2 are present in more than half of high-risk BC families [28] [29] [30] . Interestingly, the BRCA2 founder mutation observed in the French-Canadian population [30] happened to be identical to the BRCA2-8765delAG mutation found in our series (previously, we have demonstrated that such a mutation is associated with different haplotypes in Sardinian and French-Canadian families [23] ). Several authors reported that mutations of BRCA1 and BRCA2 genes in the breast site-specific cancer families would account for 20-40% of the cases, strictly depending on the total number of BC cases in the family [3, 9] (it has been even suggested that most of the families with five or fewer cases of women affected with BC and without any case of ovarian or male BC would be attributable to mutations in other lowpenetrance susceptibility genes distinct from BRCA1 and BRCA2 [4] ). In addition, the majority of the studies previously mentioned presented a higher proportion of breast-ovarian cancer families or male BC families. The low prevalence of mutations found in our study should be due to the fact that either the majority of our families [35 of 47 (74%)] contained three or four cases of female BC or a very small fraction of them were associated with ovarian and male BC. In line with this hypothesis, the percentages of BRCA1/2 mutations among families with at least five cases of BC or association with ovarian/male BC in our series were 50% or higher (Table 4) .
Considering the familial cases, BRCA2 mutations were notably more recurrent than BRCA1 mutations in the BC families from Sardinia (the very low proportion of BRCA1 mutations might be explained by the very limited number of families with association with ovarian cancer). This is in contrast to the mutation frequencies among BC families from most other populations, in which BRCA1 has been reported to play the major role in BC predisposition [17] [18] [19] [20] (BRCA2 mutations are instead prevalent in Iceland [29] ).
Generally, BRCA2 mutations have been associated with early-onset BC [31] . The median age of BC onset among all affected BRCA2 carriers from this study is similar to that reported in other studies (49 years [12, 25, 29] ). However, only 13 of 59 (22%) familial BC patients who underwent BRCA1/2 mutational analysis were diagnosed at ≤40 years of age (Table 1) , and only two (15%) of them presented the BRCA2-8765delAG mutation. Thus, our findings indicate an even lower proportion of BRCA2 mutations in very earlyonset BC families. Two generations affected (38) 7 18 Considering the incidence of the identified BRCA1/2 mutations among the unselected patients from the same population, an extensive screening was performed for the most prevalent BRCA2 germline mutation only (for the BRCA1 mutation, analysis was limited to a smaller fraction of unselected cases). Although the proportion of hereditary BC in Sardinia is estimated to be comparable with that reported for other populations [22] , the fraction of 1.4% BRCA2 mutation carriers is very low in Sardinian BC patients (although a similar prevalence was observed in the Finnish population [16] ). This is in a quite sharp contrast with frequencies in unselected cases from either the Ashkenazi Jewish population, where two BRCA1 founder mutations occur at a frequency 5-10 times higher [17, 18] , or other isolated populations [16, 20, 21] (in Iceland, a single BRCA2 founder mutation was observed in ∼10% of unselected BC patients [12, 29] ).
The association with other tumors in BC families positive for BRCA1/2 germline mutations has been widely described [10, 29, 30] and also observed in our families. In addition, patients with prostate cancer or bladder cancer from families positive for BRCA2-8765delAG (families 2, 4, 12 and 48; Table 3 ) were found to carry the same BRCA2 mutation ( [23] and G. Palomba, unpublished observations), strongly suggesting that germline alterations in such a susceptibility gene may predispose to other types of cancer.
Our study indicates that the prevalence of BRCA1 and BRCA2 germline mutations in Sardinian BC families is low. However, the presence in the family of (i) at least one case of ovarian cancer, or (ii) at least one case of male BC, or (iii) five or more cases of female BC, or (iv) three generations affected, or (v) synchronous or asynchronous bilateral BC, is a strong predictor for the presence of mutations in the BRCA1 and BRCA2 genes, which makes these kinds of family specially eligible for the mutational screening. In addition, construction of deeply rooted pedigrees in Sardinia, like that reported from Thiesi (Figure 3) , could allow us to relate a higher number of individuals, apparently unrelated at present, in very large families. This would greatly increase the number of familial members who could benefit from referral to genetic counseling.
To evaluate the biological impact of BRCA1/2 alterations in BC pathogenesis as well as to assess the existence of any correlation with the prognosis and clinical outcome, we have already started a mutational screening of these two genes in a larger subset of archival tissues from Sardinian BC patients for whom both clinical and pathological records are available (G. Palomba, unpublished data). Pedigree of the breast cancer family from Thiesi. For each individual, a generation identifier is indicated; age at diagnosis is reported for affected members. Arrows indicate the two patients positive for BRCA2-8765delAG and independently identified during the breast cancer population screening (family number is as in Table 3 ).
Finally, the majority of families studied here have remained negative for mutations in the BRCA1/2 genes, even though many showed a clear predisposition to BC. Further work is required to investigate in more details other BRCA1/2 inactivation mechanisms (i.e. mutations in the promoter regions) or mutations in other, as yet unidentified, lowpenetrance susceptibility genes. This would determine more accurately the mutation spectrum in Sardinian BC families.
